Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As in Waterloo, Iowa?
Looks like JoeBBears and shorts have a serious case of indigestion with RVVTF up 38% today
Stoke BS fear into the population, let the stock soar and get me outta here!
Reformulated Covid drug. #CovidIsNotOver $RVVTF
Americans at high risk advised to wear masks as new Covid variant detected | Coronavirus | The Guardian
https://www.theguardian.com/world/2023/aug/24/new-covid-variant-masking-high-risk-people
Ye asked how will it be funded and I responded as such so im not sure what the point of this gibberish filled response is.
I not once chimed in on whether it would be successful or not.
Focus jester.........................
How many times did he use “potential” in the last PR.
Market read it like. They see the pump as sell the news. Dropping like a rock in water
What a scam
A few more vague word salad PR’s can get him to the holidays. Happy New Years Mike
Key wording “seek to”. Not “has” or “is”. Hell anyone can say they “seek to” win the lottery
Yeah that’s his MO. Let’s see how long he can drag out bucillamine 2.0. The shareholders are giving him $30,000 bucks a month while he plays golf. Stringing investors along fits his lifestyle just fine. Why change now?
The Company will seek to initiate research studies in line with the Company’s commitment to advancing the clinical and commercial development of Bucillamine through the following strategic initiatives:
Target Indications: Novel Bucillamine in an injectable version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e. organ transplantation), acute respiratory distress syndrome, and potential medical countermeasures, that may come with regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track, and breakthrough therapy designations.
Pharmaceutical Partnerships: Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for infectious, inflammatory and respiratory disorders.
Government Support: Seek out potential funding and evaluation opportunities offered by, but not limited to, the Defence Research and Development Canada (DRDC) and the Biomedical Advanced Research and Development Authority (BARDA), the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
At this time, the Company will only provide regular updates via press releases as information becomes available.
He can’t. He’s just trying to keep this going till he can bail or has to close up shop
Upon completion of the formulation development, which is expected by end-2023, the Company will seek to initiate research studies in line with the Company’s commitment to advancing the clinical and commercial development of Bucillamine through the following strategic initiatives:
Target Indications: Novel Bucillamine in an injectable version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e. organ transplantation), acute respiratory distress syndrome, and potential medical countermeasures, that may come with regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track, and breakthrough therapy designations.
Pharmaceutical Partnerships: Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for infectious, inflammatory and respiratory disorders.
Government Support: Seek out potential funding and evaluation opportunities offered by, but not limited to, the Defence Research and Development Canada (DRDC) and the Biomedical Advanced Research and Development Authority (BARDA), the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
I believe I saw on Reddit that MF keeps a list of people he thinks might hurt him just in case something happens to him…LOL. This company is better than watching TV.
Encouraged by the news. It Certainly beats this company going totally silent like most OTC’s.
Pleased I added to lower my cost average a couple of weeks ago as that Buy segment almost at double now. Am holding all however vs “flipping” like a burger cook.
Twas a crap shoot admittedly (based on optimism surrounding Revive’s patented Bucillamine).
He took investor money at .15 per share in January when the stock was at .10. One angry person here said it was a bargain!!
Lol
Seems ""someone"" never bothered to actually read the release, or more likely, CANT READ...................
The Company has entered into a sponsored research agreement with the University of Waterloo to develop a novel lyophilized Bucillamine injectable formulation for public health medical emergencies and rare inflammatory disorders.
How is MF going to pay for this adventure? Maybe people are wising up.
Nobody is buying the big news
Unfortunate
University of Waterloo? How appropriate.
$RVVTF CounterACT Program: From Exploratory to Therapeutic Development Q&A Webinar
https://www.ninds.nih.gov/news-events/events/counteract-program-exploratory-therapeutic-development-qa-webinar
Hmmmm. How Interesting... The University of Waterloo is not that far from me.
Throwing shit at the wall to see what sticks. You got enough of a runway of cash for this two year endeavor Michael?
NEWS: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
https://ceo.ca/@GlobeNewswire/revive-therapeutics-announces-initiation-of-novel-bucillamine
COVID is chemical warfare the CEO is brilliant!. Lol but people who eat five servings of fruit vegetables a day our healthiest.
the fda already declined the drug for use for Covid
Doesn’t matter at this point how bad Covid gets. That ship has sailed. Any new indication is all investors can hope for
govprs......well whatever helps the world,would rather it be for a new varient than
chemical warfare but thats our world today.
It’s from the patent for chemical agents. Lots of threats worldwide
$RVVTF Strong buy alert from @barchart
Is this price jump from all the talk about a new variant ?
If that was done there would be a lot of civil disobedience. The government couldn't do it again, with the way it was botched prior.
Has anybody heard rumors of lockdowns or COVID restrictions coming back?
Lol...
still have shares... any fcking support for Bmt .... :)
ps.. well at least my other investment the ceo doesn't even take a Salary lol
Still, some let-up on that downward pressure... we will see.
Hi all who is smoking weed. Or dropping a liquid mushroom. This dog is not going anywhere. All the newbies stay out. It's a pump and dump.
Hi all who is smoking weed. Or dropping a liquid mushroom. This dog is not going anywhere. All the newbies stay out. It's a pump and dump.
I sure do hope so Eco.
When you are good let em know it..
Hucksters huck. He has nothing to stand on so now he is resorting to flinging insults. Hilarious. You’ve been exposed Mike. Fraud
And where has it gotten you Egomike? 2 cents USD?
P*SS of jerk off boy, go back to you basement dive.
P*ss off, I like reading his posts and DD, you should try it, you might like it? On the other hand
Sooo, I was right after all?
It Happens
Check out the BIXT board. Ecomike pumping over there as it hits a 52 week low. Called it “the next Moderna”. Those that fell for his antics lesson learned.
If pps doesn’t correct back upwards,I wont be surprised at legal action taken
Nope thus suckers well got sucked into overpaying
Surprised we haven’t seen a lawsuit
Followers
|
340
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36602
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |